Approvedregulatory verdict

Evidence outlook

Approved: Psoriasis, Psoriatic Arthritis, Crohn's Disease (label: moderately to severely active CD or UC who have had an inadequate response with, lost response to,...), Ulcerative Colitis

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (5)
JP
  • Moderately to severely active ulcerative colitis: IV induction, SC maintenance, where existing therapy is inadequatenk.jiho.jp
  • Moderately to severely active Crohn's disease: IV 130 mg induction (new) and SC 45 mg syringe maintenance (indication added)nk.jiho.jp
Product first approved 2017
UK
  • Moderately to severely active Crohn's disease and ulcerative colitis
Product first approved 2016medicines.org.uk
EU
  • Moderate to severe plaque psoriasis in adults (initial EU authorisation; PsA, Crohn's and UC added later)
Product first approved 2009EMA
CA
  • Plaque Psoriasis Stelara (ustekinumab) is indicated for: • the treatment of chronic moderate to severe plaque psoriasis in adult patients who are candidates for phototherapy or systemic therapy • the treatment of chronic moderate to severe plaque psoriasis in pediatric patients (6-17 years of age) who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies (see 1.1 Pediatrics). Psoriatic Arthritis Stelara (ustekinumab) is indicated for the treatment of adult patients with active psoriatic arthritis. Stelara can be used alone or in combination with...
Product first approved 2008Health Canada

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (39)
Crohn's Disease
NCT05299931 · Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW
2021-09-10 – 2026-05-29 · Crohn Disease
What this study did
Psoriasis
NCT04607980 · Amgen
2020-11-11 – 2022-06-03 · Plaque Psoriasis
What this study did
NCT02203032 · Janssen Research & Development, LLC
2014-10-07 – 2016-05-24 · Psoriasis
What this study did
NCT01550744 · Janssen Biotech, Inc.
2012-03 – 2015-07 · Psoriasis
What this study did
NCT01090427 · Janssen Research & Development, LLC
2010-05 – 2014-01 · Psoriasis
What this study did
NCT01091051 · Innovaderm Research Inc.
2010-03 – 2011-11 · Palmo-Plantar Pustular Psoriasis, Palmo-Plantar Pustulosis
What this study did
NCT01008995 · Centocor, Inc.
2009-10 – 2011-07 · Psoriasis
What this study did
NCT00723528 · Janssen Pharmaceutical K.K.
2008-03 – 2010-03 · Psoriasis
What this study did
NCT00454584 · Centocor, Inc.
2007-03 – 2009-01 · Psoriasis
What this study did
Psoriatic Arthritis
NCT05092269 · Janssen Research & Development, LLC
2021-10-18 – 2028-03-15 · Crohn Disease, Colitis, Ulcerative, Arthritis, Psoriatic
What this study did
NCT04610476 · University of Erlangen-Nürnberg Medical School
2020-10-19 – 2025-10-19 · Psoriatic Arthritis, Withdrawal, Reduction
What this study did
NCT04632927 · Novartis Pharmaceuticals
2020-12-21 – 2024-10-22 · Psoriatic Arthritis
What this study did
NCT03148860 · Dr. Frank Behrens
2016-12-15 – 2021-10-21 · Psoriatic Arthritis
What this study did
Ulcerative Colitis
Other / comorbidity
NCT04060888 · Janssen Research & Development, LLC
2020-07-14 – 2026-03-31 · Lupus Erythematosus, Systemic
What this study did
NCT04882072 · Janssen Pharmaceutical K.K.
2021-09-15 – 2023-05-25 · Takayasu Arteritis
What this study did
NCT04089345 · Universitaire Ziekenhuizen KU Leuven
2020-06-15 – 2023-05-01 · Pouchitis
What this study did
NCT03981744 · Janssen Pharmaceutical K.K.
2019-07-26 – 2022-07-12 · Polymyositis, Dermatomyositis
What this study did
NCT03517722 · Janssen Research & Development, LLC
2018-04-16 – 2020-11-05 · Lupus Erythematosus, Systemic
What this study did
NCT02407223 · Janssen Research & Development, LLC
2015-07-13 – 2017-09-26 · Nonradiographic Axial Spondylitis, Ankylosing
What this study did
NCT02437162 · Janssen Research & Development, LLC
2015-09-03 – 2017-09-06 · Axial Spondyloarthritis
What this study did
NCT02438787 · Janssen Research & Development, LLC
2015-07-31 – 2017-08-31 · Axial Spondyloarthritis
What this study did
Phase 2/3 (3)
Crohn's Disease
NCT03466411 · Janssen Research & Development, LLC
2018-04-13 – 2028-01-28 · Crohn's Disease
What this study did
Other / comorbidity
NCT05535738 · Wei-Che Ko
2022-11-15 – 2027-12-31 · Skin Inflammation, Allergic Contact Dermatitis
What this study did
NCT03941132 · University of British Columbia
2021-01-04 – 2026-11-01 · Type 1 Diabetes Mellitus
What this study did
Phase 2 (31)
Crohn's Disease
NCT04655807 · Janssen Research & Development, LLC
2021-03-03 – 2023-09-04 · Crohn Disease
What this study did
NCT02877134 · Janssen Research & Development, LLC
2016-08-25 – 2022-01-24 · Crohn Disease
What this study did
NCT00265122 · Centocor, Inc.
2004-04 – 2006-10 · Crohn Disease
What this study did
Psoriasis
NCT03553823 · Novartis Pharmaceuticals
2019-01-14 – 2020-01-28 · Chronic Plaque-type Psoriasis
What this study did
NCT00320216 · Centocor, Inc.
2003-11 – 2005-03 · Psoriasis
What this study did
Psoriatic Arthritis
NCT03881059 · Bristol-Myers Squibb
2019-04-01 – 2021-01-27 · Active Psoriatic Arthritis
What this study did
NCT02319759 · Janssen Research & Development, LLC
2015-03-27 – 2017-01-17 · Psoriatic Arthritis
What this study did
NCT00267956 · Centocor, Inc.
2005-12 – 2007-09 · Psoriatic Arthritis
What this study did
Other / comorbidity
NCT07268534 · Assistance Publique - Hôpitaux de Paris
2026-04-01 – 2030-04-01 · Folliculitis Decalvans (FD)
What this study did
NCT07138898 · NYU Langone Health
2025-12-12 – 2028-01 · Rheumatic Disease
What this study did
NCT04572815 · Fred Hutchinson Cancer Center
2021-05-14 – 2027-06-30 · Hematologic and Lymphocytic Disorder, Hematopoietic and Lymphoid System Neoplasm
What this study did
NCT06807593 · M.D. Anderson Cancer Center
2026-02-24 – 2027-03-31 · Cancer
What this study did
NCT07582991 · Liu Tian
2024-03-24 – 2026-02-23 · Behcet's Syndrome, Intestinal Type, Myelodysplastic Syndrome
What this study did
NCT03651518 · Assistance Publique - Hôpitaux de Paris
2020-10-20 – 2025-11-20 · Inflammatory Disease, Autoimmune Diseases
What this study did
NCT03711448 · Centre Hospitalier Universitaire Dijon
2019-01-07 – 2024-09-11 · Patients Relapsing Refractory Giant Cell Arteritis
What this study did
NCT03847272 · Centre Hospitalier Universitaire Dijon
2019-08-01 – 2023-10-25 · Patients With Newly Diagnosed Active NISU
What this study did
NCT04117932 · CHU de Reims
2020-03-11 – 2023-06-22 · Bullous Pemphigoid
What this study did
NCT02911116 · National Eye Institute (NEI)
2017-03-30 – 2020-05-28 · Uveitis
What this study did
NCT02648581 · Assistance Publique - Hôpitaux de Paris
2017-06-14 – 2019-11-19 · Behçet Disease
What this study did
NCT02349061 · Janssen Research & Development, LLC
2015-10-15 – 2019-03-13 · Lupus Erythematosus, Systemic
What this study did
NCT01713400 · H. Lee Moffitt Cancer Center and Research Institute
2013-02-25 – 2018-06-14 · Graft vs. Host Disease
What this study did
NCT02204397 · Jewish General Hospital
2015-11 – 2017-03-08 · Type 1 Diabetes Mellitus
What this study did
NCT01806662 · Rockefeller University
2013-03 – 2015-03 · Atopic Dermatitis
What this study did
NCT01945086 · Janssen Pharmaceutical K.K.
2013-09 – 2014-12 · Dermatitis, Atopic
What this study did
NCT01704534 · University Medical Center Groningen
2012-05 – 2014-04 · Hidradenitis Suppurativa
What this study did
NCT01389973 · Janssen Research & Development, LLC
2011-09 – 2013-06 · Primary Biliary Cirrhosis
What this study did
NCT01330901 · Charite University, Berlin, Germany
2011-10 – 2013-05 · Ankylosing Spondylitis
What this study did
NCT00207727 · Centocor, Inc.
2004-07 – 2006-08 · Multiple Sclerosis
What this study did
Phase 1/2 (5)
Other / comorbidity
NCT03366142 · National Institute of Allergy and Infectious Diseases (NIAID)
2018-07-02 – 2024-10-17 · LAD1
What this study did
NCT02199496 · National Institute of Allergy and Infectious Diseases (NIAID)
2015-10-19 – 2020-07-10 · Gastrointestinal Inflammation Associated With CVID, CVID Enteropathy
What this study did
NCT02955147 · Massachusetts General Hospital
2016-12-01 – 2019-09-19 · Giant Cell Arteritis, Temporal Arteritis, Horton's Disease
What this study did
NCT02117765 · University of British Columbia
2015-03 – 2017-06 · Type 1 Diabetes
What this study did
NCT01647152 · National Eye Institute (NEI)
2012-07-03 – 2015-06-30 · Uveitis
What this study did
Phase 1 (16)
Crohn's Disease
NCT05725876 · University Medical Center Groningen
2025-01-06 – 2027-01-06 · Psoriasis, Crohn Disease
What this study did
NCT02968108 · Janssen Research & Development, LLC
2017-01-18 – 2022-03-18 · Crohn Disease
What this study did
Psoriasis
NCT04744363 · Alvotech Swiss AG
2021-05-25 – 2022-03-19 · Psoriasis
What this study did
NCT02763969 · Bristol-Myers Squibb
2016-05-18 – 2016-12-15 · Psoriasis
What this study did
NCT01276847 · Merck Sharp & Dohme LLC
2011-03 – 2011-12 · Psoriasis
What this study did
Psoriatic Arthritis
NCT05252533 · Janssen Research & Development, LLC
2022-05-24 – 2024-01-26 · Juvenile Psoriatic Arthritis, Psoriasis, Arthritis, Juvenile
What this study did
Ulcerative Colitis
NCT06742606 · Ain Shams University
2025-01-15 – 2026-12-13 · Effect of Drug
What this study did
NCT03358706 · Janssen Research & Development, LLC
2018-02-02 – 2021-11-22 · Crohn Disease, Ulcerative Colitis
What this study did
Other / comorbidity
NCT04549792 · Northwestern University
2021-04-01 – 2024-06-26 · Ichthyosis
What this study did
NCT04093531 · University of Rochester
2020-01-15 – 2022-05-11 · Primary Sjögren Syndrome
What this study did
NCT04816513 · Janssen Research & Development, LLC
2021-04-14 – 2022-01-26 · Healthy
What this study did
NCT04030533 · Janssen Research & Development, LLC
2019-11-29 – 2020-12-31 · Healthy
What this study did
NCT02156375 · Janssen Research & Development, LLC
2014-05 – 2014-12 · Healthy
What this study did
NCT01081704 · Centocor, Inc.
2009-10 – 2010-06 · Healthy
What this study did
Phase 4 (19)
Crohn's Disease
NCT06520397 · Sixth Affiliated Hospital, Sun Yat-sen University
2024-07-15 – 2027-07-31 · Crohn Disease
What this study did
NCT06045754 · Takeda
2024-04-18 – 2027-06-28 · Crohn's Disease
What this study did
NCT04496063 · Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
2020-11-16 – 2025-12-30 · Crohn's Disease
What this study did
NCT05029921 · Janssen Research & Development, LLC
2021-12-10 – 2025-05-18 · Crohn Disease
What this study did
NCT05861167 · Sixth Affiliated Hospital, Sun Yat-sen University
2023-06-01 – 2024-06-01 · Crohn Disease
What this study did
NCT04629196 · NYU Langone Health
2022-02-16 – 2024-01-17 · Crohn Disease
What this study did
Psoriasis
NCT07352566 · University of California, San Francisco
2026-08-01 – 2030-06-01 · Psoriasis, Atopic Dermatitis
What this study did
NCT05270733 · University Hospitals Cleveland Medical Center
2022-11-10 – 2026-12-31 · Psoriasis
What this study did
NCT02144857 · University of Athens
2014-05-30 – 2023-12-31 · Psoriasis
What this study did
NCT02187172 · University of Pennsylvania
2014-07 – 2018-09-11 · Psoriasis, Cardiovascular Disease
What this study did
NCT02693470 · Chang Gung Memorial Hospital
2014-08 – 2016-07 · Psoriasis With Cell-derived Microparticles
What this study did
NCT01511315 · University of California, San Francisco
2012-03 – 2014-12 · Psoriasis
What this study did
NCT01558310 · Paul Steven Yamauchi, MD, PhD
2012-08 – 2013-12 · Scalp Psoriasis, Plaque Psoriasis
What this study did
NCT01059773 · Janssen-Cilag International NV
2009-10 – 2011-08 · Psoriasis
What this study did
Ulcerative Colitis
NCT07576452 · University Hospital, Clermont-Ferrand
2026-12-01 – 2030-12-01 · Ulcerative Colitis (UC)
What this study did
NCT06788340 · Odense University Hospital
2026-01-23 – 2028-11-30 · Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
What this study did
NCT07303686 · McGill University Health Centre/Research Institute of the McGill University Health Centre
2025-10-08 – 2027-10-15 · Crohn Disease (CD), Ulcerative Colitis (UC)
What this study did
NCT03629379 · Universitaire Ziekenhuizen KU Leuven
2019-01-22 – 2021-07-01 · Inflammatory Bowel Diseases, Psoriasis
What this study did
Other / comorbidity
NCT04996485 · National Medical Research Center for Children's Health, Russian Federation
2021-03-01 – 2023-06-01 · Congenital Ichthyosis
What this study did
Early phase / not applicable (8)
Crohn's Disease
NCT06912815 · Xiang Gao
2024-08-01 – 2026-09 · Crohn Disease (CD)
What this study did
NCT04779762 · Wolfson Medical Center
2022-01 – 2026-01 · Crohn Disease
What this study did
NCT06455267 · The Third Xiangya Hospital of Central South University
2024-04-01 – 2025-09-30 · Mild to Severe Crohns Disease
What this study did
NCT04795960 · University of Michigan
2021-03-18 – 2023-03 · Crohn Disease
What this study did
NCT03712826 · Hospices Civils de Lyon
2022-07-24 – 2022-07-24 · Crohn Disease
What this study did
Psoriasis
NCT01090063 · Tufts Medical Center
2010-02 – 2012-04 · Moderate to Severe Palmar Plantar Psoriasis
What this study did
NCT00870285 · Medical University of Graz
2009-03 – 2011-04 · Psoriasis
What this study did
Ulcerative Colitis
NCT07529236 · Centre Hospitalier Universitaire de Nice
2026-04-20 – 2027-10-01 · Chronic Inflammatory Bowel Diseases
What this study did
Used as active comparator (33)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (25)
Crohn's Disease
NCT07149467 · Sixth Affiliated Hospital, Sun Yat-sen University
2025-09-10 – 2027-12-31 · Crohn's Disease Aggravated, Crohn's Disease in Remission
What this study did
NCT03926130 · Eli Lilly and Company
2019-07-23 – 2023-10-02 · Crohn's Disease
What this study did
Psoriasis
NCT07116967 · Bristol-Myers Squibb
2025-09-22 – 2031-01-16 · Plaque Psoriasis
What this study did
NCT06425549 · UCB Biopharma SRL
2024-06-25 – 2030-11-08 · Moderate to Severe Plaque Psoriasis
What this study did
NCT06934226 · Janssen Research & Development, LLC
2025-04-15 – 2027-08-20 · Plaque Psoriasis
What this study did
NCT06488664 · AO GENERIUM
2023-07-25 – 2025-11-26 · Plaque Psoriasis
What this study did
NCT05335356 · Biocon Biologics UK Ltd
2022-06-28 – 2023-11-15 · Moderate to Severe Chronic Plaque Psoriasis
What this study did
NCT04728360 · Bio-Thera Solutions
2021-07-06 – 2023-07-07 · Plaque Psoriasis
What this study did
NCT04305327 · LEO Pharma
2022-12-07 – 2023-05-05 · Psoriasis
What this study did
NCT04967508 · Samsung Bioepis Co., Ltd.
2021-07-06 – 2022-11-25 · Psoriasis, Moderate to Severe Plaque Psoriasis
What this study did
NCT04785326 · Dong-A ST Co., Ltd.
2021-04-28 – 2022-11-16 · Moderate to Severe Chronic Plaque Psoriasis
What this study did
NCT04930042 · Alvotech Swiss AG
2021-06-03 – 2022-10-11 · Psoriasis
What this study did
NCT04673786 · Celltrion
2021-01-11 – 2022-05-12 · Psoriasis
What this study did
NCT02826603 · Novartis Pharmaceuticals
2016-06-22 – 2018-07-09 · Plaque Psoriasis
What this study did
NCT02786732 · MedDerm Associates
2012-08 – 2017-10 · Psoriasis
What this study did
NCT02561806 · Eli Lilly and Company
2015-10 – 2017-10 · Plaque Psoriasis
What this study did
NCT02684357 · AbbVie
2016-03 – 2017-09 · Psoriasis
What this study did
NCT02074982 · Novartis Pharmaceuticals
2014-02-26 – 2016-06-29 · Chronic Plaque Type Psoriasis
What this study did
NCT01708603 · Bausch Health Americas, Inc.
2012-08 – 2015-10 · Moderate to Severe Plaque Psoriasis
What this study did
NCT01708629 · Bausch Health Americas, Inc.
2012-09 – 2015-10 · Plaque Psoriasis
What this study did
Psoriatic Arthritis
NCT03370133 · UCB Biopharma SRL
2017-12-06 – 2019-12-13 · Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis, Psoriatic Arthritis
What this study did
Ulcerative Colitis
NCT07177118 · First Affiliated Hospital of Wenzhou Medical University
2025-10-20 – 2028-10-20 · Crohn Disease, Crohn Disease and Ulcerative Colitis
What this study did
Phase 2 (2)
Psoriasis
NCT02054481 · Boehringer Ingelheim
2014-02 – 2015-07 · Psoriasis
What this study did
Ulcerative Colitis
NCT06453317 · Medical University of Lodz
2025-02-17 – 2028-06-30 · Ulcerative Colitis, Inflammatory Bowel Diseases
What this study did
Phase 1/2 (1)
Crohn's Disease
NCT03167437 · National Institute of Allergy and Infectious Diseases (NIAID)
2017-10-30 – 2035-06-30 · Crohn's Disease
What this study did
Phase 1 (5)
Psoriasis
NCT04843631 · BioFactura Australia Pty Ltd.
2021-04-01 – 2021-12-08 · Psoriasis
What this study did
NCT04371185 · Bio-Thera Solutions
2020-08-08 – 2021-04-19 · Psoriasis
What this study did
Other / comorbidity
NCT05890118 · RANI Therapeutics
2023-08-30 – 2023-11-28 · Healthy Volunteers
What this study did
NCT06481215 · AO GENERIUM
2022-03-11 – 2022-12-20 · Healthy Volunteers
What this study did
NCT04428814 · Celltrion
2020-08-03 – 2021-02-24 · Healthy Subjects
What this study did
Appears in other studies (5)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (1)
Psoriasis
NCT04761627 · Amgen
2021-03-24 – 2023-02-28 · Psoriasis
What this study did
Phase 2 (2)
Crohn's Disease
NCT04978493 · Boehringer Ingelheim
2021-12-02 – 2024-08-08 · Crohn Disease
What this study did
Psoriasis
NCT01999868 · National Institute of Allergy and Infectious Diseases (NIAID)
2014-03-19 – 2018-03-01 · Psoriasis
What this study did
Phase 4 (2)
Crohn's Disease
NCT05928039 · University of Calgary
2023-10-25 – 2028-12-31 · Crohn Disease
What this study did
Ulcerative Colitis
NCT03885713 · Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
2019-09-10 – 2024-12-31 · Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
What this study did

Competitive landscape

7 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Crohn's Disease: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Ustekinumab (Stelara): this drugApprovedMonoclonal antibodyIL-12 p40Reliable signal
NCT01369355: Number of Participants With Clinical Remission at Week 44 (Week 44): Placebo Subcutaneously (SC) 47/131 (35.9%) vs Ustekinumab 90 Milligram (mg) SC Every 12 Weeks (q12w) 63/129 (48.8%) vs Ustekinumab 90 mg SC q8w 68/128 (53.1%); p=0.040 (Placebo Subcutaneously (SC) vs Ustekinumab 90 Milligram (mg) SC Every 12 Weeks (q12w)), p=0.005 (Placebo Subcutaneously (SC) vs Ustekinumab 90 mg SC q8w)
NCT01369342: Number of Participants With Clinical Response at Week 6 (Week 6): Placebo 60/209 (28.7%) vs Ustekinumab 130 mg 108/209 (51.7%) vs Ustekinumab Approximately (~) 6 Milligram Per Kilogram (mg/kg) 116/209 (55.5%); p=< 0.001 (Placebo vs Ustekinumab 130 mg), p=< 0.001 (Placebo vs Ustekinumab Approximately (~) 6 Milligram Per Kilogram (mg/kg))
Adalimumab (Humira)ApprovedMonoclonal antibodyTNF-alphaPartial signal
NCT02499783: Percentage of Participants Who Achieved Clinical Remission (CDAI < 150) at Week 4 (Week 4): Double-Blind Period, Weeks 0 to 4: Placebo 6.8% vs Double-Blind Period, Weeks 0 to 4: Adalimumab 160/80 mg 37.3%; p=<0.001 (Double-Blind Period, Weeks 0 to 4: Placebo vs Double-Blind Period, Weeks 0 to 4: Adalimumab 160/80 mg)
NCT02065570: Percentage of Participants Who Achieved Clinical Remission at Week 4 (Week 4): Induction: Standard Induction Dose 43.7% vs Induction: Higher Induction Dose 43.5%; p=0.939 (Induction: Standard Induction Dose vs Induction: Higher Induction Dose) missed
Adalimumab-Aacf (Idacio)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Aaty (Yuflyma)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Adaz (Hyrimoz)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Adbm (Cyltezo)ApprovedMonoclonal antibodyTNF-alphaReliable signal
NCT02871635: Clinical response (CDAI decrease of 70 points or more) at week 4, BI 695501 vs Humira (modified full analysis set): 61/68 (90%) vs 68/72 (94%); adjusted risk ratio 0.945 (90% CI 0.870 to 1.028), lower limit above the exploratory non-inferiority margin of 0.76 (Hanauer 2021, Lancet Gastroenterol Hepatol).
Adalimumab-Afzb (Abrilada)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Aqvh (Yusimry)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Atto (Amjevita)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Bwwd (Hadlima)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Fkjp (Hulio)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Ryvk (Simlandi)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Budesonide (Entocort EC)ApprovedSmall moleculeGlucocorticoid receptorWeak signalFeatured results are safety only in this race
Budesonide (Ortikos)
ApprovedUS marketing discontinued
—Glucocorticoid receptornot yet gradedNo reviewed efficacy summary in this indication
Certolizumab Pegol (Cimzia)ApprovedAntibody fragmentTNF-alphaWeak signal
NCT00552058: Clinical remission at Week 6: 31.6% (95% CI 25.4-37.8) certolizumab pegol vs 25.4% (95% CI 19.5-31.3) placebo; no p-value reported missed
NCT00297648: Mean Change From Baseline in CDEIS (Crohn's Disease Endoscopic Index of Severity) Score at Week 10 Using Local Non-blinded Assessments (Baseline, Week 10): CDP870 400 mg -6.47 score on a scale (95% CI -7.6 to -5.34)
DexamethasoneApprovedSmall moleculeGlucocorticoid receptornot yet gradedNo reviewed efficacy summary in this indication
Guselkumab (Tremfya)ApprovedMonoclonal antibodyIL-23 p19Reliable signal
QUASAR/GALAXI: superior to ustekinumab on pooled endoscopic endpoints
Infliximab (Remicade)ApprovedMonoclonal antibodyTNF-alphaReliable signal
NCT00094458: Percentage of Participants With Corticosteriod-free Clinical Remission (Week 26): Azathioprine + Placebo 30.0% vs Infliximab + Placebo 44.4% vs Infliximab + Azathioprine 56.8%; p=<0.001 (Azathioprine + Placebo vs Infliximab + Azathioprine), p=0.006 (Azathioprine + Placebo vs Infliximab + Placebo), p=0.022 (Infliximab + Placebo vs Infliximab + Azathioprine)
NCT00269841: Primary end point achieved by 68% (5 mg/kg) and 56% (10 mg/kg) vs 26% on placebo (P=0.002 and P=0.02).
Infliximab-Abda (Renflexis)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Infliximab-Axxq (Avsola)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Infliximab-Dyyb (Inflectra)ApprovedMonoclonal antibodyTNF-alphaReliable signal
NCT02096861: CDAI-70 response at Week 6: CT-P13 69.4% (77/111) vs originator infliximab 74.3% (81/109); difference -4.9% (95% CI -16.9 to 7.3), above the -20% non-inferiority margin
Infliximab-Dyyb (Zymfentra)ApprovedMonoclonal antibodyTNF-alphaReliable signalNo reviewed efficacy summary in this indication
Infliximab-Qbtx (Ixifi)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
MethylprednisoloneApprovedSmall moleculeGlucocorticoid receptor agonistnot yet gradedNo reviewed efficacy summary in this indication
Mirikizumab (Omvoh)ApprovedMonoclonal antibodyIL-23 p19Reliable signal
NCT03926130: Percentage of Adult Participants Achieving Clinical Response at Week 12 and Endoscopic Response at Week 52 (Placebo and Mirikizumab) (Week 12 to Week 52): Placebo 9.0% (95% CI 5.1-13.0) vs Mirikizumab 38.0% (95% CI 34.0-42.0); p=<0.000001 (Placebo vs Mirikizumab)
Natalizumab (Tysabri)ApprovedMonoclonal antibodyα4 integrinPartial signal
NCT00032799: Week 10 clinical response (CDAI decrease >=70): natalizumab 56% vs placebo 49% (P=0.05); remission (CDAI <150): 37% vs 30% (P=0.12) missed
Risankizumab (Skyrizi)ApprovedMonoclonal antibodyIL-23 p19Reliable signal
NCT03104413: US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission (Week 12): Placebo (Induction Period 1) 19.8% (95% CI 14.1-25.5) vs Risankizumab 600mg (Induction Period 1) 42.0% (95% CI 34.9-49.0) vs Risankizumab 1200mg (Induction Period 1) 40.3% (95% CI 33.4-47.3); p=<0.001 (Placebo (Induction Period 1) vs Risankizumab 600mg (Induction Period 1)), p=< 0.001 (Placebo (Induction Period 1) vs Risankizumab 1200mg (Induction Period 1))
NCT03105128: US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission (Week 12): Placebo (Period 1) 24.6% (95% CI 18.2-31.0) vs Risankizumab 600mg (Period 1) 45.2% (95% CI 39.9-50.5) vs Risankizumab 1200mg (Period 1) 41.6% (95% CI 36.3-46.8); p=<0.001 (Placebo (Period 1) vs Risankizumab 600mg (Period 1)), p=<0.001 (Placebo (Period 1) vs Risankizumab 1200mg (Period 1))
Upadacitinib (Rinvoq)ApprovedSmall moleculeJAK, JAK1Reliable signal
NCT03345849: Percentage of Participants With Clinical Remission Per Crohn's Disease Activity Index (CDAI) at Week 12 (Week 12): Placebo 29.1% (95% CI 22.4-35.8) vs Upadacitinib 45 mg QD 49.5% (95% CI 44.2-54.8); p=<0.0001 (Placebo vs Upadacitinib 45 mg QD)
NCT03345836: Percentage of Participants With Clinical Remission Per Crohn's Disease Activity Index (CDAI) at Week 12 (Week 12): Part 1 (Double Blind): Placebo 21.1% (95% CI 14.9-27.2) vs Part 1 (Double Blind): Upadacitinib 45 mg 38.9% (95% CI 33.6-44.2); p=<0.0001 (Part 1 (Double Blind): Placebo vs Part 1 (Double Blind): Upadacitinib 45 mg)
Ustekinumab-Aauz (Otulfi)Approved—IL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Aekn (Selarsdi)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Auub (Wezlana)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Hmny (Starjemza)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Srlf (Imuldosa)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Stba (Steqeyma)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Ttwe (Pyzchiva)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Vedolizumab (Entyvio)ApprovedMonoclonal antibodyα4β7 integrinPartial signal
NCT02611817: Percentage of Participants Achieving Clinical Remission at Week 52 (Week 52): Maintenance Phase: Induction IV + Placebo 34.3% (95% CI 26.3-43.0) vs Maintenance Phase: Induction IV + Vedolizumab 108 mg SC 48.0% (95% CI 42.0-54.1); p=0.008 (Maintenance Phase: Induction IV + Placebo vs Maintenance Phase: Induction IV + Vedolizumab 108 mg SC)
NCT03234907: Percentage of Participants With Enhanced Clinical Response in the Induction Phase at Week 10 (Week 10): Induction Phase: Placebo 24.3% (95% CI 14.8-36.0) vs Induction Phase: Vedolizumab 300 mg 19.4% (95% CI 13.3-26.9); p==0.347 (Induction Phase: Placebo vs Induction Phase: Vedolizumab 300 mg) missed
AfimkibartPhase 3Monoclonal antibodyTL1Anot yet gradedNo reviewed efficacy summary in this indication
DuvakitugPhase 3Monoclonal antibodyTL1APartial signal
NCT05499130: UC cohort, clinical remission at week 14: 36% (450 mg) / 48% (900 mg) vs 20% placebo, placebo-adjusted 16% (p=.050) / 27% (p=.003). CD cohort, endoscopic response: 26.1% (low dose) / 47.8% (high dose) vs 13.0% placebo. P-values are one-sided at a 0.10 significance level.
JNJ-78934804Phase 3CombinationIL-23 p19, TNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Remestemcel-L (Ryoncil)Phase 3Cell therapyAllogeneic MSC therapyPartial signalNo reviewed efficacy summary in this indication
TH-SC01Phase 3Cell therapyMesenchymal stem cells (MSC)Weak signalNo reviewed efficacy summary in this indication
Tirzepatide (Zepbound)Phase 3PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
TulisokibartPhase 3Monoclonal antibodyTL1Anot yet gradedNo reviewed efficacy summary in this indication
Icotrokinra (Icotyde)Phase 2/3PeptideIL-23 receptornot yet gradedNo reviewed efficacy summary in this indication
AmiselimodPhase 2Small moleculeS1P receptorPartial signal
NCT02378688: Proportion achieving CDAI-100 response at Week 12: amiselimod 0.4mg 19/39 (48.7%) vs placebo 20/37 (54.1%); odds ratio 0.79, 95% CI [0.31, 1.98], not statistically significant. missed
AVB-114Phase 2Cell therapyImplantable cell/biomaterial constructPartial signal
NCT04847739: Combined remission at 9 months: 45.8% (11/24) with AVB-114 vs 8.3% (2/24) with standard of care; difference 38% (95% CI 11 to 60%) (2025-10-29).
AZD7798Phase 2Monoclonal antibodyCCR9Weak signalFeatured results are safety only in this race
ExoFloPhase 2Cell therapyMSC-derived exosomesWeak signalFeatured results are safety only in this race
Golimumab (Simponi)Phase 2Monoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
MT-201Phase 2Biologic (subtype unspecified)—not yet gradedNo reviewed efficacy summary in this indication
MT-501Phase 2Small molecule—not yet gradedNo reviewed efficacy summary in this indication
ObefazimodPhase 2Small moleculemiR-124not yet gradedNo reviewed efficacy summary in this indication
OmilancorPhase 2Small moleculeLANCL2not yet gradedNo reviewed efficacy summary in this indication
ZotemtegrastPhase 2Small moleculeα4β7 integrinnot yet gradedNo reviewed efficacy summary in this indication
EcoActivePhase 1/2Microbiome therapeuticBacteriophage (anti-AIEC)not yet gradedNo reviewed efficacy summary in this indication
Furestem-CDPhase 1/2Cell therapyAllogeneic MSC therapyWeak signalNo reviewed efficacy summary in this indication
ICG318Phase 1/2Cell therapyBCMA / CD19not yet gradedNo reviewed efficacy summary in this indication
ALLO-ASCPhase 1Cell therapyAdipose-derived MSC therapyWeak signalNo reviewed efficacy summary in this indication
BDHK-2009Phase 1Small molecule—not yet gradedNo reviewed efficacy summary in this indication
Hemay007Phase 1Small moleculeTNF-alphaWeak signalNo reviewed efficacy summary in this indication
HRS-7085Phase 1Small moleculeNCBP1/NCBP2 (nuclear cap-binding complex)Weak signalNo reviewed efficacy summary in this indication
IPG11406Phase 1Small moleculeEBI2Weak signalFeatured results are safety only in this race
LMT503Phase 1Small moleculeMacrophage polarization / Cellular metabolismnot yet gradedNo reviewed efficacy summary in this indication
OD-07656Phase 1Small moleculeRIPK2Weak signalNo reviewed efficacy summary in this indication
PALI-2108Phase 1Small moleculePDE4not yet gradedNo reviewed efficacy summary in this indication
R-3750Phase 1Biologic (subtype unspecified)Dendritic cell targetingnot yet gradedNo reviewed efficacy summary in this indication
TQH3906Phase 1Small moleculeTYK2not yet gradedNo reviewed efficacy summary in this indication
ABBV-7066
—(overall)
UndisclosedIL-23 + TL1Anot yet gradedNo reviewed efficacy summary in this indication

Large race: only the 67 furthest-along competitors are listed; 4 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(13 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Stelara (ustekinumab) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
December 2026 (2)
Phase 4Crohn's DiseaseRecruiting
Est. primary completion 2026-12-31 · NCT06520397 · CT.gov ↗
What to watch
Phase 4PsoriasisRecruiting
Est. primary completion 2026-12-31 · NCT05270733 · CT.gov ↗
What to watch
2027 (7)
January 2027 (1)
Phase 2/3Skin Inflammation, Allergic Contact DermatitisActive not recruiting
Est. primary completion 2027-01-01 · NCT05535738 · CT.gov ↗
What to watch
March 2027 (1)
Phase 2CancerRecruiting
Est. primary completion 2027-03-31 · NCT06807593 · CT.gov ↗
What to watch
April 2027 (1)
Phase 4Crohn's DiseaseRecruiting
Est. primary completion 2027-04-15 · NCT07303686 · CT.gov ↗
What to watch
June 2027 (1)
Phase 4Crohn's DiseaseActive not recruiting
Est. primary completion 2027-06-28 · NCT06045754 · CT.gov ↗
What to watch
September 2027 (1)
Phase 3Psoriatic ArthritisActive not recruiting
Est. primary completion 2027-09-29 · NCT05092269 · CT.gov ↗
What to watch
October 2027 (1)
Early phase / not applicablePsoriasisRecruiting
Est. primary completion 2027-10-01 · NCT07529236 · CT.gov ↗
What to watch
December 2027 (1)
Phase 4Crohn's DiseaseEnrolling by invitation
Est. primary completion 2027-12-30 · NCT06788340 · CT.gov ↗
What to watch
2028 (1)
January 2028 (1)
Phase 2Rheumatic DiseaseRecruiting
Est. primary completion 2028-01 · NCT07138898 · CT.gov ↗
What to watch
2029 (1)
November 2029 (1)
Phase 2Folliculitis Decalvans (FD)Not yet recruiting
Est. primary completion 2029-11-01 · NCT07268534 · CT.gov ↗
What to watch
2030 (2)
June 2030 (2)
Phase 4PsoriasisNot yet recruiting
Est. primary completion 2030-06-01 · NCT07352566 · CT.gov ↗
What to watch
Phase 4Ulcerative ColitisNot yet recruiting
Est. primary completion 2030-06-01 · NCT07576452 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

28 August 2026ApprovalFDA approves Stelara for pediatric ulcerative colitis
US, FDA · Janssen · Source ↗
15 April 2026ApprovalFDA approves Stelara for pediatric Crohn's disease
US, FDA · Johnson & Johnson · Source ↗